Pharmacokinetics and metabolism of metoprolol and propranolol in the female DA and female Wistar rat: The female DA rat is not always an animal model for poor metabolizers of CYP2D6

Journal of Pharmaceutical Sciences

Volumn 94, Issue 2, 2005, Pages 397-408

  Komura, Hiroshi ^a   Iwaki, Masahiro ^a  

^a KINKI UNIVERSITY   (Japan)

Author keywords

CYP2D; DA rat; Genetic polymorphism; Metabolism; Metoprolol; Nonlinearity; Pharmacokinetics; Propranolol

Indexed keywords

CYTOCHROME P450 2D6; METOPROLOL; PROPRANOLOL; QUININE;

ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG METABOLISM; ENZYME SUBSTRATE; FEMALE; GENETIC POLYMORPHISM; IN VITRO STUDY; IN VIVO STUDY; KINETICS; MALE; NONHUMAN; NONLINEAR SYSTEM; PROTEIN BINDING; RAT; RAT STRAIN; STRAIN DIFFERENCE;

EID: 14344255557     PISSN: 00223549     EISSN: None     Source Type: Journal    
DOI: 10.1002/jps.20255     Document Type: Article

References (41)

1. Ingelman-Sundberg M. 2001. Genetic susceptibil-ity to adverse effects of drugs and environmental toxicants. The role of the CYP family of enzymes. Mutat Res 482:11-19.
2. Bertilsson L, Dahl ML, Dalen P, Al-Shurbaji A. 2002. Molecular genetics of CYP2D6: Clinical relevance with focus on psychotropic drugs. Br J Clin Pharmacol 53:111-122.
3. Masimirembwa CM, Thompson R, Andersson TB. 2001. In vitro high throughput screening of compounds for favorable metabolic properties in drug discovery. Comb Chem High Throughput Screening 4:245-263.
4. Ansede JH, Thakker DR. 2004. High-throughput screening for stability and inhibitory activity of compounds toward cytochrome P450-mediated metabolism. J Pharm Sci 93:239-255.
5. Yamamoto Y, Tasaki T, Nakamura A, Iwata H, Kazusaka A, Gonzalez FJ, Fujita S. 1998. Molecular basis of the Dark Agouti rat drug oxidation polymorphism: Importance of CYP2D1 and CYP2D2. Pharmacogenetics 8:73-82.
6. Kahn GC, Rubenfield M, Davies DS, Murray S, Boobis AR. 1985. Sex and strain differences in hepatic debrisoquine 4-hydroxylase activity of the rat. Drug Metab Dispos 13:510-516.
7. Suzuki T, Narimatsu S, Fujita S, Masubuchi Y, Umeda S. 1991. Impairment of bunitrolol 4-hydroxylase activity in liver microsomes of dark agouti rats. Biochem Pharmacol 42:2241-2244.
8. Narimatsu S, Tachibana M, Masubuchi Y, Imaoka S, Funae Y, Suzuki T. 1995. Cytochrome P450 isozymes involved in aromatic hydroxylation and side-chain N-desisopropylation of alprenolol in rat liver microsomes. Biol Pharm Bull 18:1060-1065.
9. Barham HM, Lennard MS, Tucker GT. 1994. An evaluation of cytochrome P450 isoform activities in the female dark agouti (DA) rat: Relevance to its use as a model of the CYP2D6 poor metaboliser phenotype. Biochem Pharmacol 47:1295-1307.
10. Al-Dabbagh SG, Idle JR, Smith RL. 1981. Animal modeling of human polymorphic drug oxidation-The metabolism of debrisoquine and phenacetin in rat inbred strains. J Pharm Pharmacol 33:161-164.
11. Law MYL, Moody DE. 1994. Urinary excretion of amphetamine and 4′-hydroxyamphetamine by Sprague Dawley and dark Agouti rats. Life Sci 54:1073-1079.
12. Zysset T, Zeugin T, Kupfer A. 1988. In-vivo and in-vitro dextromethorphan metabolism in SD and DA rat. An animal model of the debrisoquine-type polymorphic oxidation in man. Biochem Pharmacol 37:3155-3160.
13. Muralidharan G, Midha KK, McKay G, Hawes EM, Inaba T. 1989. Selective in vivo inhibition by quinidine of methoxyphenamine oxidation in rat models of human debrisoquine polymorphism. Xenobiotica 19:189-197.
14. Staack RF, Paul LD, Springer D, Kraemer T, Maurer HH. 2004. Cytochrome P450 dependent metabolism of the new designer drug 1-(3-trifluoromethylphenyl) piperazine (TFMPP): In vivo studies in Wistar and Dark Agouti rats as well as in vitro studies in human liver microsomes. Biochem Pharmacol 67:235-244.
15. Guttendorf RJ, Kostenbauder HB, Wedlund PJ. 1991. Stereoselective differences in propranolol disposition in female Sprague-Dawley and Dark Agouti rats. Drug Metab Dispos 19:251-256.
16. Raghuram TC, Koshakji RP, Wilkinson GR, Wood AJ. 1984. Polymorphic ability to metabolize propranolol alters 4-hydroxypropranolol levels but not beta blockade. Clin Pharmacol Ther 36:51-56.
17. Lennard MS, Jackson PR, Freestone S, Tucker GT, Ramsay LE, Woods HF. 1984. The relationship between debrisoquine oxidation phenotype and the pharmacokinetics and pharmacodynamics of propranolol. Br J Clin Pharmacol 17:679-685.
18. Bertz RJ, Granneman GR. 1997. Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions. Clin Pharmacokinet 32:210-258.
19. Vincent-Viry M, Deshayes S, Mothe O, Siest G, Galteau MM. 1988. Hydroxylation of debrisoquine using perfused liver isolated from Sprague Dawley Dawley and DA rats: Comparison with in vivo results. J Pharm Pharmacol 40:695-700.
20. Obach RS, Reed-Hagen AE. 2002. Measurement of Michaelis constants for cytochrome P450-mediated biotransformation reactions using a substrate depletion approach. Drug Metab Dispos 30:831-837.
21. Bradford MM. 1976. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72:248-254.
22. Kobayashi K, Urashima K, Shimada N, Chiba K. 2002. Substrate specificity for rat cytochrome P450 (CYP) isoforms: Screening with cDNA-expressed systems of the rat. Biochem Pharmacol 63:889-896.
23. Palamanda JR, Favreau L, Lin C, Nomeir AA. 1998. Validation of a rapid microtiter plate assay to conduct cytochrome P450 2D6 enzyme inhibition studies. Drug Metab Discov 3:466-470.
24. Ito K, Ogihara K, Kanamitsu S, Ito T. 2003. Prediction of the in vivo interaction between midazolam and microlicles based on in vitro studies using human liver microsomes. Drug Metab Dispos 31: 945-954.
25. Yamaoka K, Tanigawara Y, Nakagawa T, Uno T. 1981. A pharmacokinetic analysis program (multi) for microcomputer. J Pharmabiodyn 4:879-885.
26. Kobayashi S, Murray S, Watson D, Sesardic D, Davies DS, Boobis AR. 1989. The specificity of inhibition of debrisoquine 4-hydroxylase activity by quinidine and quinine in the rat is the inverse of that in man. Biochem Pharmacol 38:2795-2799.
27. Masubuchi Y, Kagimoto N, Narimatsu S, Fujita S, Suzuki T. 1993. Regioselective contribution of the cytochrome P-450 2D subfamily to propranolol metabolism in rat liver microsomes. Drug Metab Dispos 21:1012-1016.
28. Walle T, Oatis JE Jr, Walle UK, Knapp DR. 1982. New ring-hydroxylated metabolites of propranolol: Species differences and stereospecific 7-hydroxylation. Drug Metab Dispos 10:122-127.
29. Nelson WL, Bartels MJ. 1984. N-dealkylation of propranolol in rat, dog, and man. Chemical and stereochemical aspects. Drug Metab Dispos 12: 345-352.
30. Fujita S, Umeda S, Funae Y, Imaoka S, Abe H, Ishida R, Adachi T, Masuda M, Kazusaka A, Suzuki T. 1993. Regio- and stereoselective propranolol metabolism by 15 forms purified cytochrome P-450 from rat liver. J Pharmacol Exp Ther 264:226-233.
31. Lennard MS, Crewe HK, Tucker GT, Woods HF. 1986. Metoprolol oxidation by rat liver microsomes. Inhibition by debrisoquine and other drugs. Biopharm Pharmacol 35:2757-2761.
32. Obach RS. 1999. Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: An examination of in vitro half-life approach and nonspecific binding to microsomes. Drug Metab Dispos 27:1350-1359.
33. Obach RS. 1997. Nonspecific binding to microsomes: impact on scale-up of in vitro intrinsic clearance to hepatic clearances as assessed through examination of warfarin, imipramine, and propranolol. Drug Metab Dispos 25:1359-1369.
34. Hiroi T, Imaoka S, Chow T, Funae Y. 1998. Tissue distribution of CYP2D1, 2D2, 2D3 and 2D4 mRNA in rats detected by RT-PCR. Biochim Biophys Acta 1380:305-312.
35. Hiroi T, Chow T, Imaoka S, Funae Y. 2002. Catalytic specificity of CYP2D isoforms in rat and human. Drug Metab Dispos 30:970-976.
36. Schulz-Utermoehl T, Bennett AJ, Ellis SW, Tucker GT, Boobis AR, Edwards RJ. 1999. Polymorphic debrisoquine 4-hydroxylase activity in the rat is due to differences in CYP2D2 expression. Pharmacogenetics 9:357-366.
37. Narimatsu S, Kobayashi N, Masubuti Y, Horie T, Kakegawa T, Kobayashi H, Hardwick JP, Gonzalez FJ, Shimada N, Ohmori S, Kitada M, Asaoka K, Kataoka H, Yamamoto S, Satoh T. 2000. Species difference in enantioselectivity for the oxidation of propranolol by cytochrome P450 2D enzymes. Chem Biol Interact 127:73-90.
38. McGinnity DF, Parker AJ, Soars M, Riley R. 2000. Automated definition of the enzymology of drug oxidation by the major human drug metabolizing cytochrome P450s. Drug Metab Dispos 28:1327-1334.
39. Midha KK, Roscoe RM, Wilson TW, Cooper JK, Loo JC, Ho-Ngoc A, McGilveray IJ. 1983. Pharmacokinetics of glucuronidation of propranolol following oral administration in humans. Biopharm Drug Dispos 4:331-338.
40. Naritomi Y, Terashita S, Kimura S, Suzuki A, Kagayama A, Sugiyama Y. 2001. Prediction of human hepatic clearance from in vivo animal experiments and in vitro metabolic studies with liver microsomes from animal and humans. Drug Metab Dispos 29:1316-1324.
41. Dey M, Brisson J, Davis G, Enever R, Pray K, Zaim B, Dvornik D. 1986. Relationship between plasma propranolol concentration and dose in young, healthy volunteers. Biopharm Drug Dispos 7:103-111.